Brokerages Set Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Price Target at $42.89

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been given an average rating of “Moderate Buy” by the eleven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $43.10.

A number of research firms have weighed in on TEVA. Leerink Partners began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday. They set an “outperform” rating and a $45.00 target price on the stock. UBS Group raised their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Weiss Ratings cut Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $37.01 on Friday. The business’s 50-day moving average price is $34.91 and its two-hundred day moving average price is $33.37. Teva Pharmaceutical Industries has a 12-month low of $18.21 and a 12-month high of $38.37. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The stock has a market cap of $43.13 billion, a PE ratio of 61.68, a P/E/G ratio of 4.53 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. As a group, analysts expect that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC raised its stake in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after acquiring an additional 292 shares during the last quarter. Captrust Financial Advisors grew its stake in shares of Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after purchasing an additional 302 shares during the last quarter. Banque Cantonale Vaudoise increased its holdings in Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after purchasing an additional 306 shares during the period. Ethic Inc. increased its holdings in Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after purchasing an additional 325 shares during the period. Finally, Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.